Sanofi (Paris, FR / Cambridge, MA) sponsors 328 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 103 active protocols (48 recruiting now), 152 completed protocols, and 132 all-time original FDA Drugs@FDA NDA and BLA approvals.